Immune Design Corp (IMDZ) Shares Bought by Vanguard Group Inc

Vanguard Group Inc boosted its stake in Immune Design Corp (NASDAQ:IMDZ) by 0.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,615,442 shares of the biotechnology company’s stock after acquiring an additional 11,006 shares during the period. Vanguard Group Inc’s holdings in Immune Design were worth $5,574,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Marshall Wace LLP purchased a new stake in Immune Design in the third quarter valued at approximately $36,000. Bank of America Corp DE raised its stake in shares of Immune Design by 231.9% during the second quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 32,669 shares during the last quarter. Northern Trust Corp raised its stake in shares of Immune Design by 11.0% during the second quarter. Northern Trust Corp now owns 357,880 shares of the biotechnology company’s stock worth $1,628,000 after purchasing an additional 35,439 shares during the last quarter. Nexthera Capital LP purchased a new stake in shares of Immune Design during the third quarter worth approximately $146,000. Finally, Bridgeway Capital Management Inc. raised its stake in shares of Immune Design by 172.1% during the third quarter. Bridgeway Capital Management Inc. now owns 221,192 shares of the biotechnology company’s stock worth $763,000 after purchasing an additional 139,900 shares during the last quarter. Hedge funds and other institutional investors own 46.29% of the company’s stock.

Get Immune Design alerts:

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Immune Design in a research note on Monday, January 14th. Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. Finally, ValuEngine upgraded Immune Design from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $7.13.

Shares of Immune Design stock remained flat at $$1.53 during trading hours on Tuesday. The stock had a trading volume of 23,035 shares, compared to its average volume of 207,333. Immune Design Corp has a twelve month low of $1.10 and a twelve month high of $5.05. The stock has a market capitalization of $73.69 million, a PE ratio of -0.87 and a beta of 2.47.

In other Immune Design news, major shareholder Bvf Partners L. P/Il sold 902,000 shares of the stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $1.83, for a total value of $1,650,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 927,466 shares of company stock valued at $1,690,895 in the last 90 days. Company insiders own 18.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4146555/immune-design-corp-imdz-shares-bought-by-vanguard-group-inc.html.

About Immune Design

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Read More: What are the Different Types of Leveraged Buyouts?

Want to see what other hedge funds are holding IMDZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immune Design Corp (NASDAQ:IMDZ).